Liposomal delivery system/adjuvant for tuberculosis vaccine.

Area of Science:

• Immunology
• Vaccinology
• Nanotechnology

Background:

• Tuberculosis (TB) remains a global health crisis, with millions infected and dying annually.
• A significant number of TB deaths occur in individuals co-infected with HIV.
• The development of effective TB vaccines is crucial to combat the disease's high infection and mortality rates.

Purpose of the Study:

• To review the current research landscape of adjuvants for tuberculosis vaccines.
• To specifically investigate the potential of liposomal adjuvant systems in TB vaccine development.

Main Methods:

• Literature review of current TB adjuvant research.
• Focus on liposomal adjuvant systems, analyzing their characteristics and efficacy.

Main Results:

• Liposomal adjuvant systems demonstrate safety and efficiency across nano- to micro-size ranges.
• These systems are suitable for vaccinations against TB, other intracellular infections, and malignancies.
• Protein subunit vaccines for TB show higher protection compared to traditional vaccines.

Conclusions:

• Liposomal systems represent a promising platform for developing next-generation TB vaccines.
• Clinical studies are essential for refining novel TB adjuvants and maximizing vaccine impact.
• Adjuvants are critical components for enhancing the efficacy of TB vaccines in clinical trials.